May 26, 2026 | Benefits preservation, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
A recent Pharmaceutical Strategies Group analysis shows managing specialty drug costs is now the top priority for employer health plans —surpassing total cost of care. MedBen Rx’s Benefit Preservation Program addresses this by reducing specialty drug spend by an...
Feb 23, 2026 | Biosimilar, Cost Savings, MedBen Rx, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Aug 11, 2025 | Benefits preservation, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
Specialty medications continue to drive a disproportionate share of prescription drug costs – often accounting for 60% or more of a pharmacy plan’s total spend. MedBen Rx’s Benefit Preservation helps plans manage these expenses without compromising...
Jul 1, 2025 | Benefits preservation, Diabetes, GLP-1s, MedBen Rx, Ozempic, Rebates, Specialty Drugs, Spread Pricing, Transparency, Wegovy, Weight loss, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
Feb 24, 2025 | Benefits preservation, Case Study, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
High-cost specialty drugs can make up more than 60% of a health plan’s pharmacy costs. MedBen Rx’s benefit preservation program is designed to make certain that members have continued access to medications while reducing specialty drug spend to the greatest...
Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
